Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Instituciones de las que forman parte Jefe de grupo Investigación biomédica con Células Madre de Cáncer Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Matilde Lleonart Pajarin LinkedIn Twitter Orcid Instituciones de las que forman parte Jefe de grupo Investigación biomédica con Células Madre de Cáncer Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Proyectos Identificación de nuevos factores pronóstico y diagnóstico en cáncer basados en microRNAs y sus proteínas diana que se asocian a tumores de carácter más agresivo IP: Matilde Lleonart Pajarin Colaboradores: Angel García Jiménez, Teresa Moline Marimon, Carmela Iglesias i Felip, Vicente Peg Camara Entidad financiadora: Instituto de Salud Carlos III Financiación: 145200 Referencia: PI12/01104 Duración: 01/01/2013 - 30/06/2017 Desarrollo de dianas terapéuticas basadas en microRNAs sobreexpresados en cáncer de pulmón IP: Matilde Lleonart Pajarin Colaboradores: - Entidad financiadora: Fundación BBVA Financiación: 147000 Referencia: BBVA/CONV.LLEONART/2010 Duración: 01/06/2010 - 01/06/2014 Genetic screen for detecting genes expressed in embryonic stem cells that bypass immortalisation in primary cells IP: Matilde Lleonart Pajarin Colaboradores: - Entidad financiadora: EUROPEAN COMMISSION Financiación: 31959 Referencia: MERG-510300 Duración: 01/02/2004 - 31/01/2005 Desarrollo de dianas terapéuticas basadas en micro-RNAs sobreexpresados en cáncer IP: Matilde Lleonart Pajarin Colaboradores: - Entidad financiadora: Fundación Caja Navarra Financiación: 9463.18 Referencia: CAN2009-16708 Duración: 01/01/2010 - 31/12/2010 Paginación Primera página « Página anterior ‹ … Página 3 Página 4 Página actual 5 Página 6 Página 7 … Siguiente página › Última página »
